Sometimes I can’t help but voice a bit of skepticism, especially when it comes to sexual disorder treatments. So, count me as less than convinced about this experimental treatment from Boehringer-Ingelheim – Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo…more (the single-question Patient Benefit Evaluation appears to me to be really…ummm…meaningful).
Lung cancer preventer for former smokers? Interesting – A drug approved to treat a range of conditions may also work to prevent lung cancer in people who have given up smoking, U.S. researchers reported on Tuesday…more
AstraZeneca replaces Nexium sales force with telemarketers. And it works.
J&J‘s recall of OTC products. This is becoming a huge black eye, for a company that managed to keep quite a good reputation over the years. It will be an interesting case study of reputation management and quality improvement, esp. for a company that has been a leader in social media usage in this sector.
Compliance and Diversity. The Impactiviti partner network has the providers you need for corporate training – including diversity, compliance, ethics, and much more! Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
JUST FOR FUN
I only rarely get to see hailstorms. That’s what makes this video particularly awesome. Must be seen to be believed!
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board